Bicycle Therapeutics plc Operating Expenses
Bicycle Therapeutics plc (BCYC) reported Operating Expenses of $55.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-07-30
- Bicycle Therapeutics plc operating expenses for the quarter ending 2026-06-30 was $55.19M, a 38.35% decline year-over-year.
- Bicycle Therapeutics plc operating expenses for the quarter ending 2026-03-31 was $66.37M, a 17.23% decline year-over-year.
- Bicycle Therapeutics plc operating expenses for the quarter ending 2025-12-31 was $72.66M, a 1.81% increase year-over-year.
- Bicycle Therapeutics plc operating expenses for the quarter ending 2025-09-30 was $77.28M, a 16.18% increase year-over-year.
- Bicycle Therapeutics plc operating expenses for fiscal 2025 was $319.65M, a 30.39% increase from fiscal 2024.
- Bicycle Therapeutics plc operating expenses for fiscal 2024 was $245.15M, a 13.01% increase from fiscal 2023.
- Bicycle Therapeutics plc operating expenses for fiscal 2023 was $216.92M, a 65.44% increase from fiscal 2022.
- Bicycle Therapeutics plc operating expenses for fiscal 2022 was $131.12M, a 69.59% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $55.19M 10-Q · filed 2026-07-30 | $121.56M 10-Q · filed 2026-07-30 | $194.22M derived: sum of 3 quarters · filed 2026-07-30 | $271.50M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $66.37M 10-Q · filed 2026-04-30 | $139.03M derived: sum of 2 quarters · filed 2026-04-30 | $216.32M derived: sum of 3 quarters · filed 2026-04-30 | $305.84M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $72.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $149.95M derived: sum of 2 quarters · filed 2026-03-17 | $239.47M derived: sum of 3 quarters · filed 2026-07-30 | $319.65M 10-K · filed 2026-03-17 |
| 2025-09-30 | $77.28M 10-Q · filed 2025-10-30 | $166.81M derived: sum of 2 quarters · filed 2026-07-30 | $246.99M 10-Q · filed 2025-10-30 | $318.36M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $89.52M 10-Q · filed 2026-07-30 | $169.70M 10-Q · filed 2026-07-30 | $241.07M derived: sum of 3 quarters · filed 2026-07-30 | $307.60M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $80.18M 10-Q · filed 2026-04-30 | $151.55M derived: sum of 2 quarters · filed 2026-04-30 | $218.07M derived: sum of 3 quarters · filed 2026-04-30 | $274.08M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $71.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $137.89M derived: sum of 2 quarters · filed 2026-03-17 | $193.90M derived: sum of 3 quarters · filed 2026-03-17 | $245.15M 10-K · filed 2026-03-17 |
| 2024-09-30 | $66.52M 10-Q · filed 2025-10-30 | $122.53M derived: sum of 2 quarters · filed 2025-10-30 | $173.78M 10-Q · filed 2025-10-30 | $233.34M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $56.01M 10-Q · filed 2025-08-08 | $107.25M 10-Q · filed 2025-08-08 | $166.82M derived: sum of 3 quarters · filed 2026-03-17 | $222.97M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $51.25M 10-Q · filed 2025-05-01 | $110.81M derived: sum of 2 quarters · filed 2026-03-17 | $166.96M derived: sum of 3 quarters · filed 2026-03-17 | $221.47M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $59.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $115.72M derived: sum of 2 quarters · filed 2026-03-17 | $170.22M derived: sum of 3 quarters · filed 2026-03-17 | $216.92M 10-K · filed 2026-03-17 |
| 2023-09-30 | $56.15M 10-Q · filed 2024-10-31 | $110.66M derived: sum of 2 quarters · filed 2024-10-31 | $157.36M 10-Q · filed 2024-10-31 | $192.75M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $54.51M 10-Q · filed 2024-08-06 | $101.21M 10-Q · filed 2024-08-06 | $136.60M derived: sum of 3 quarters · filed 2025-02-25 | $169.40M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $46.70M 10-Q · filed 2024-05-02 | $82.09M derived: sum of 2 quarters · filed 2025-02-25 | $114.89M derived: sum of 3 quarters · filed 2025-02-25 | $146.57M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $35.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $68.19M derived: sum of 2 quarters · filed 2025-02-25 | $99.87M derived: sum of 3 quarters · filed 2025-02-25 | $131.12M 10-K · filed 2025-02-25 |
| 2022-09-30 | $32.80M 10-Q · filed 2023-11-02 | $64.48M derived: sum of 2 quarters · filed 2023-11-02 | $95.72M 10-Q · filed 2023-11-02 | $117.52M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $31.68M 10-Q · filed 2023-08-03 | $62.92M 10-Q · filed 2023-08-03 | $84.72M derived: sum of 3 quarters · filed 2024-02-20 | $103.34M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $31.24M 10-Q · filed 2023-05-04 | $53.04M derived: sum of 2 quarters · filed 2024-02-20 | $71.67M derived: sum of 3 quarters · filed 2024-02-20 | $90.73M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $21.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $40.42M derived: sum of 2 quarters · filed 2024-02-20 | $59.48M derived: sum of 3 quarters · filed 2024-02-20 | $77.31M 10-K · filed 2024-02-20 |
| 2021-09-30 | $18.63M 10-Q · filed 2022-11-03 | $37.69M derived: sum of 2 quarters · filed 2022-11-03 | $55.52M 10-Q · filed 2022-11-03 | $76.43M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $19.06M 10-Q · filed 2022-08-04 | $36.89M 10-Q · filed 2022-08-04 | $57.80M derived: sum of 3 quarters · filed 2022-08-04 | $72.32M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $17.83M 10-Q · filed 2022-05-05 | $38.74M derived: sum of 2 quarters · filed 2022-05-05 | $53.26M derived: sum of 3 quarters · filed 2022-05-05 | $67.41M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $20.91M 10-K · filed 2021-03-11 | $35.42M derived: sum of 2 quarters · filed 2021-11-04 | $49.58M derived: sum of 3 quarters · filed 2021-11-04 | $62.35M 10-K · filed 2023-02-28 |
| 2020-09-30 | $14.52M 10-Q · filed 2021-11-04 | $28.67M derived: sum of 2 quarters · filed 2021-11-04 | $41.44M 10-Q · filed 2021-11-04 | $51.49M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $14.15M 10-Q · filed 2021-08-05 | $26.93M 10-Q · filed 2021-08-05 | $36.97M derived: sum of 3 quarters · filed 2021-08-05 | $47.84M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $12.77M 10-Q · filed 2021-05-06 | $22.82M derived: sum of 2 quarters · filed 2021-05-06 | $33.68M derived: sum of 3 quarters · filed 2021-05-06 | $43.19M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $10.04M 10-K · filed 2021-03-11 | $20.91M derived: sum of 2 quarters · filed 2021-03-11 | $30.42M derived: sum of 3 quarters · filed 2021-03-11 | $40.10M 10-K · filed 2022-03-01 |
| 2019-09-30 | $10.87M 10-K · filed 2021-03-11 | $20.38M derived: sum of 2 quarters · filed 2021-03-11 | $30.05M 10-Q · filed 2020-11-05 | $38.65M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $9.51M 10-K · filed 2021-03-11 | $19.19M 10-Q · filed 2020-08-05 | $27.79M derived: sum of 3 quarters · filed 2021-03-11 | $35.75M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $9.68M 10-K · filed 2021-03-11 | $18.28M derived: sum of 2 quarters · filed 2021-03-11 | $26.24M derived: sum of 3 quarters · filed 2021-03-11 | $32.86M derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | $8.60M 10-K · filed 2020-03-10 | $16.57M derived: sum of 2 quarters · filed 2020-03-10 | $23.18M derived: sum of 3 quarters · filed 2020-03-10 | $28.88M 10-K · filed 2021-03-11 |
| 2018-09-30 | $7.97M 10-K · filed 2020-03-10 | $14.59M derived: sum of 2 quarters · filed 2020-03-10 | $20.28M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $6.62M 10-K · filed 2020-03-10 | $12.32M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $5.70M 10-K · filed 2020-03-10 | |||
| 2017-12-31 | $18.27M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |